Stocks
News
ETFs
Economy
Currencies
Press Releases
Innate Pharma S.A. - American Depositary Shares (IPHA)
Last Price
2.1900
Change
-0.0100 (-0.45%)
NASDAQ
· Last Trade: Jun 1st, 3:27 PM EDT
Quote
News
Press Releases
Chart
Historical
FAQ
About
Competitors
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 27, 2025
Outcome of Innate Pharma’s 2025 Annual General Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 23, 2025
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 23, 2025
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 19, 2025
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 15, 2025
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 13, 2025
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 12, 2025
Innate Pharma announces conference call and webcast for Q1 2025 business update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 6, 2025
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 30, 2025
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 29, 2025
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 28, 2025
Innate Pharma Announces €15M Investment by Sanofi
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 24, 2025
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 23, 2025
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 16, 2025
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 16, 2025
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 3, 2025
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 27, 2025
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 26, 2025
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 25, 2025
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 20, 2025
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· February 27, 2025
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· February 17, 2025
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 27, 2025
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 21, 2025
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 16, 2025
